Palazestrant in the clinic.
Our lead investigational drug, palazestrant (OP-1250), is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal.
Our pipeline
Target Patient Population
Discovery
Nonclinical
Phase I
Phase II
Phase III
Clinical
Collaboration
Palazestrant (OP-1250) - ER+/HER2- Metastatic Breast Cancer
1st line combo with CDK 4/6i ribociclib
2/3 line monotherapy
Combo therapy with CDK4/6i ribociclib
Combo therapy with CDK4/6i palbociclib
Combo therapy with PI3Ki alpelisib with PIK3CA mutated
Combo therapy with mTOR inhibitor everolimus
OP-3136 KAT6 Inhibitor - Breast Cancer and Other Solid Tumors
ER+/HER2- metastatic breast cancer/castrate-resistant prostate/lung cancer